Similar articles for PMID: 25711240

Year	Number of Results
1961	1
1975	1
1976	1
1977	1
1979	3
1984	1
1987	1
1988	1
1989	2
1990	2
1993	1
1994	1
1996	3
1998	4
1999	1
2000	3
2002	5
2004	2
2005	3
2006	1
2008	2
2009	1
2010	3
2011	1
2012	4
2013	5
2014	10
2015	9
2016	12
2017	5
2018	5
2020	2
2021	0

1

Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.

Abdelmoneim AS, Eurich DT, Light PE, Senior PA, Seubert JM, Makowsky MJ, Simpson SH. Abdelmoneim AS, et al. Diabetes Obes Metab. 2015 Jun;17(6):523-532. doi: 10.1111/dom.12456. Epub 2015 Mar 20. Diabetes Obes Metab. 2015. PMID: 25711240 Review.

2

Do sulphonylureas still have a place in clinical practice?

Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ. Khunti K, et al. Lancet Diabetes Endocrinol. 2018 Oct;6(10):821-832. doi: 10.1016/S2213-8587(18)30025-1. Epub 2018 Feb 28. Lancet Diabetes Endocrinol. 2018. PMID: 29501322 Review.

3

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ. Krentz AJ, et al. Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005. Drugs. 2005. PMID: 15669880 Review.

4

Comparative tolerability of sulphonylureas in diabetes mellitus.

Harrower AD. Harrower AD. Drug Saf. 2000 Apr;22(4):313-20. doi: 10.2165/00002018-200022040-00004. Drug Saf. 2000. PMID: 10789825 Review.

5

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.

Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T. Hemmingsen B, et al. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009008. doi: 10.1002/14651858.CD009008.pub2. Cochrane Database Syst Rev. 2013. PMID: 23633364 Updated. Review.

6

Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.

Scheen AJ. Scheen AJ. Diabetes Metab. 2018 Nov;44(5):386-392. doi: 10.1016/j.diabet.2018.05.007. Epub 2018 Jun 2. Diabetes Metab. 2018. PMID: 30126735 Review.

7

[Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?].

Asvold BO, Jonsbu M, Grill V. Asvold BO, et al. Tidsskr Nor Laegeforen. 2000 Sep 10;120(21):2560-4. Tidsskr Nor Laegeforen. 2000. PMID: 11070997 Review. Norwegian.

8

Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.

Huupponen R. Huupponen R. Med Toxicol. 1987 May-Jun;2(3):190-209. doi: 10.1007/BF03259864. Med Toxicol. 1987. PMID: 3298923 Review.

9

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.

Gooßen K, Gräber S. Gooßen K, et al. Diabetes Obes Metab. 2012 Dec;14(12):1061-72. doi: 10.1111/j.1463-1326.2012.01610.x. Epub 2012 May 17. Diabetes Obes Metab. 2012. PMID: 22519906 Review.

10

[Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA® trial].

Gallwitz B, Thiemann S, Wörle HJ, Marx N. Gallwitz B, et al. Dtsch Med Wochenschr. 2015 May;140(11):831-4. doi: 10.1055/s-0041-102194. Epub 2015 May 28. Dtsch Med Wochenschr. 2015. PMID: 26080724 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed